Program chair Aditya Bardia, MD, MPH, invites you to PER®’s complimentary in-person and virtual satellite symposium.
Join Aditya Bardia, MD, MPH, and other leading experts at PER®’s Medical Crossfire®: Evaluating the Potential Role of Next-Generation Selective Estrogen Receptor Degraders in the ER+/HER2- Breast Cancer on June 4, 2022.
Lasofoxifene Combo Yields Meaningful Activity in ER+/HER2– Breast Cancer
June 6th 2023The anti-tumor activity of lasofoxifene plus abemaciclib does not appear to be compromised by co-occurring alterations that confer resistance among patients with estrogen receptor–positive HER2-negative breast cancer.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
Abemaciclib Combo Maintains Efficacy in Older HER2– Breast Cancer Population
June 3rd 2023Older patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer maintain a clinically meaningful absolute reduction in risk of distant relapse and invasive disease following treatment with abemaciclib and endocrine therapy.
2 Clarke Drive
Cranbury, NJ 08512